HTG Molecular Diagnostics Inc(HTGM)stock report

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

HTG Molecular Diagnostics, Inc. is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The Company’s HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples. The Company’s HTG EdgeSeq chemistry, together with its HTG Edge or HTG EdgeSeq instrumentation and software, automates and adapts its nuclease protection chemistry to enable analysis using next generation sequencing (NGS) instrumentation. The HTG EdgeSeq system utilizes substantially the same sample preparation reagents as its original chemistry, but allows for read out on an NGS instrument.

Market Cap:46.1M; Shares Outstanding:58.0M; Short Interest: 4.55%; Q3 2019(9/30/19): Cash 37.88M. Loss 4.74M

EPS and Sales:

Date EPS % last year % last quarter
2018.12.31 -0.6 66.48% -13.21%
2019.3.31 -0.19 13.64% 68.33%
2019.6.30 -0.36 0.00% -89.47%
2019.9.30 -0.5 5.66% -38.89%


Date Sales % last year % last quarter
2018.12.31 21.5M 45.69% 56.02%
2019.3.31 3.2M -22.98% -85.12%
2019.6.30 9M -0.77% 181.25%
2019.9.30 14.4M 4.56% 60.00%


Insider Transactions:

Institution Ownership:

Total institutions: 54,no change
Shares hold: 22598.5k shares. no change
shares% hold: 38.93%,no change

Analyst Ratings:

Leave a Reply